TrialAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2022

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.

Ivar S Jensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.